MDS WHO Classification-based Prognostic Scoring System (WPSS)

Estimate survival and risk of transformation to AML in myelodysplastic syndrome.

The global unit selector only affects unanswered questions
1.WHO Category?
2.Karyotype?
3.Transfusion Requirement?
Created by

1. WHO Category?

Created by
0/3 completed

About this Calculator

Although the International Prognostic Scoring System remains the most validated prognostic scoring system for myelodysplasia (MDS), its current application is limited to the time of MDS diagnosis. The WHO prognostic scoring system (WPSS) has the advantage of being dynamic and validated throughout the disease course. The WPSS investigators studied a cohort of 426 MDS patients from Pavia, Italy and subsequently validated the prognostic scoring system in 739 patients diagnosed in Dusseldorf, Germany. The most important variables for the prognostic model were WHO diagnostic classification, karyotype, and transfusion requirement. The scoring system identified five risk groups showing different probabilities of survival (ranging from 12 months to 103 months) and transformation to acute myeloid leukemia (with 5-year risk ranging from 6% to 100%). However, some concerns remain surrounding the replacement of the IPSS with the WPSS. In particular, the criteria for transfusion dependence may be subject to significant practice variation.

The WPSS was proposed and validated by Malcovati et al. (Time-dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. JCO 2007;25:3503-3510). An accompanying criticism of the WPSS is also available from Bowen et al. (Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and pratical application. JCO 2008;26(7):1180).

References

Malcovati et al.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007 August 10, 25 (23): 3503-10

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.